Recent data concerning heparanase: Focus on fibrosis, inflammation and cancer

Biomolecular Concepts

Volumn 6, Issue 5-6, 2015, Pages 415-421

  Secchi, Maria Francesca ^a   Masola, Valentina ^b   Zaza, Gianluigi ^b   Lupo, Antonio ^b   Gambaro, Giovanni ^c   Onisto, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

cancer; extracellular matrix; fibrosis; heparan sulfate; heparanase; inflammation

Indexed keywords

BETA GLUCURONIDASE; HEPARAN SULFATE; HEPARANASE;

BIOLOGICAL MODEL; ENZYMOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; HUMAN; INFLAMMATION; KIDNEY; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; INFLAMMATION; KIDNEY; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84948680999     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc-2015-0021     Document Type: Article

References (64)

1. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007; 446: 1030-7.
2. Theocharis A, Gialeli C, Hascall V, Karamanos NK. Extracellular matrix: a functional scaffold. In: Karamanos NK, editor. Extracellular matrix: pathobiology and signaling. Berlin: Walter de Gruyter, 2012: 3-19.
3. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011; 209: 139-51.
4. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai- Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
5. Vreys V, David G. Mammalian heparanase: what is the message?. J Cell Mol Med 2007; 11: 427-52.
6. Shteingauz A, Ilan N, Vlodavsky I. Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and á-actinin. Cell Mol Life Sci 2014; 71: 4457-70.
7. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004; 117(Pt 11): 2249-58.
8. Nobuhisa T, Naomoto Y, Takaoka M, Tabuchi Y, Ookawa K, Kitamoto D, Gunduz E, Gunduz M, Nagatsuka H, Haisa M, Matsuoka J, Nakajima M, Tanaka N. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem Biophys Res Commun 2005; 331: 175-80.
9. Nobuhisa T, Naomoto Y, Okawa T, Takaoka M, Gunduz M, Motoki T, Nagatsuka H, Tsujigiwa H, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Kurebayashi J, Nakajima M, Taniguchi S, Sagara J, Dong J, Tanaka N. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci 2007; 98: 535-40.
10. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O. Human heparanase nuclear localization and enzymatic activity. Lab Invest 2004; 84: 535-44.
11. Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD. Heparanase-mediated loss of nuclear syndecan- 1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 2011; 286: 30377-83.
12. Wang F, Wang Y, Zhang D, Puthanveetil P, Johnson JD, Rodrigues B. Fatty acid-induced nuclear translocation of heparanase uncouples glucose metabolism in endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32: 406-14.
13. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279: 23536-41.
14. Yuan L, Hu J, Luo Y, Liu Q, Li T, Parish CR, Freeman C, Zhu X, Ma W, Hu X, Yu H, Tang S. Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylation. Mol Vis 2012; 18: 1684-95.
15. Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase AKT activation and its integrin dependence. J Biol Chem 2013; 288: 12366-75.
16. Hu X, Zhang L, Jin J, Zhu W, Xu Y, Wu Y, Wang Y, Chen H, Webster KA, Chen H, Yu H, Wang J. Heparanase released from mesenchymal stem cells activates integrin beta1/HIF-2á/Flk-1 signaling and promotes endothelial cell migration and angiogenesis. Stem Cells 2015; 33: 1850-62.
17. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, Vlodavsky I. Heparanase mediate cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015-25.
18. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, Alon R, Lider O. Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 2004; 172: 5185-93.
19. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 2006; 66: 1455-63.
20. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N. Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007; 361: 829-34.
21. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I, Ilan N. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009; 69: 1758-67.
22. Rockey DC, Bell PD, Hill JA. Fibrosis-A common pathway to organ injury and failure. N Engl J Med 2015; 372: 1138-49.
23. He W, Dai C. Key fibrogenic signaling. Curr Pathobiol Rep 2015; 3: 183-192.
24. Lamouille S, Xu J, Derynck R. Molecular mechanism of epithelial to mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-96.
25. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A. Masola V. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 2011; 1813: 1475-82.
26. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M, Lupo A. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelialmesenchymal transition in renal tubular cells. J Biol Chem 2012; 287: 1478-88.
27. Masola V, Zaza G, Secchi MF, Gambaro G, Lupo A, Onisto M. Heparanase is a key player in renal fibrosis by regulating TGF - Â expression and activity. Biochim Biophys Acta 2014; 1843: 2122-8.
28. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, van der Vlag J, Vlodavsky I, Elkin M. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61: 208-16.
29. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 2012; 10: 213.
30. Davids JS1, Carothers AM, Damas BC, Bertagnolli MM. Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila) 2010; 3: 348-58.
31. Ikeguchi M, Hirooka Y, Kaibara N. Heparanase gene expression and its correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and carcinoma. Eur J Cancer 2003; 39: 86-90.
32. Xiao Y, Kleeff J, Shi X, B?chler MW, Friess H. Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatol Res 2003; 26: 192-98.
33. Ohayon O, Mawasi N, Pevzner A, Tryvitz A, Gildor T, Pines M, Rojkind M, Paizi M, Spira G. Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. Lab Invest 2008; 88: 627-33.
34. Goldshmidt O, Yeikilis R, Mawasi N, Paizi M, Gan N, Ilan N, Pappo O, Vlodavsky I, Spira G. Heparanase expression during normal liver development and following partial hepatectomy. J Pathol 2004; 203: 594-602.
35. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006; 6: 633-43.
36. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
37. Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005; 6: 902-10.
38. Brunn GJ, Bungum MK, Johnson GB, Platt JL. Conditional signaling by Toll-like receptor 4. FASEB J 2005; 19: 872-4.
39. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H, Andersson R. TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 2011; 9: 219.
40. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, Rubinstein AM, Elkin M. Versatile role of heparanase in inflammation. Matrix Biol 2013; 32: 234-40.
41. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, Meirovitz A, Peretz T, Vlodavsky I, Elkin M. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011; 121: 1709-21.
42. Goodall KJ, Poon IK, Phipps S, Hulett MD. Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One 2014; 9: e109596.
43. Lygizos MI, Yang Y, Altmann CJ, Okamura K, Hernando AA, Perez MJ, Smith LP, Koyanagi DE, Gandjeva A, Bhargava R, Tuder RM, Faubel S,Schmidt EP. Heparanase mediates renal dysfunction during early sepsis in mice. Physiol Rep 2013; 1: e00153.
44. Goldberg R, Rubinstein AM, Gil N, Hermano E, Li JP, van der Vlag J, Atzmon R, Meirovitz A, Elkin M. Role of heparanase- driven inflammatory cascade in pathogenesis of diabetic nephropathy. Diabetes 2014; 63: 4302-13.
45. Morris A, Wang B, Waern I, Venkatasamy R, Page C, Schmidt EP, Wernersson S, Li JP, Spina D. The role of heparanase in pulmonary cell recruitment in response to an allergic but not nonallergic stimulus. PLoS One 2015; 10: e0127032.
46. Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T, Elkin M. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst 2014; 106: dju332.
47. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Antiinflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci 2015; 2015: 507151.
48. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983; 220: 611-3.
49. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 1983; 43: 2704-11.
50. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I, Abramovitch R. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006; 118: 1609-17.
51. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004; 96: 1219-30.
52. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I, Elkin M. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 2008; 14: 668-76.
53. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010; 277: 3890-903.
54. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-39.
55. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011; 30: 253-68.
56. Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol 2014; 4: 195.
57. Zong F, Fthenou E, Wolmer N, Holl?si P, Kovalszky I, Szilák L, Mogler C, Nilsonne G, Tzanakakis G, Dobra K. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One 2009; 4: e7346.
58. Cao HJ, Fang Y, Zhang X, Chen WJ, Zhou WP, Wang H, Wang LB, Wu JM. Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor êB in human gastric carcinoma tissue. World J Gastroenterol 2005; 11: 903-7.
59. Wu W, Pan C, Meng K, Zhao L, Du L, Liu Q, Lin R. Hypoxia activates heparanase expression in an NF-êB dependent manner. Oncol Rep 2010; 23: 255-61.
60. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, Ilan N, Doweck I, Vlodavsky I. Heparanase induces signal transducer and activator of transcription (STAT) protein phosphorylation: preclinical and clinical significance in head and neck cancer. J Biol Chem 2012; 287: 6668-78.
61. Yang Y, Gorzelanny C, Bauer AT, Halter N, Komljenovic D, B?uerle T, Borsig L, Roblek M, Schneider SW. Nuclear heparanase- 1 activity suppress melanoma progression via its DNA-binding affinity. Oncogene 2015; Mar 9. doi: 10.1038/onc.2015.40.
62. Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I, Ilan N, Vlodavsky I. Heparanase enhances tumor growth and chemo-resistance by promoting autophagy. Cancer Res 2015; 75: 3946-57.
63. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 2015; 21: 524-9.
64. Masola V, Secchi MF, Gambaro G, Onisto M. Heparanase as a target in cancer therapy. Curr Cancer Drug Targets 2014; 14: 286-93.